FDA Outlines Ways to Assess Analytical, Clinical Performance of NGS ahead of February Workshop | GenomeWeb

NEW YORK (GenomeWeb) – The US Food and Drug Administration is considering a standards-based approach for assessing the analytical performance of next-generation sequencing diagnostic tests and using centralized curated databases to evaluate their clinical performance, according to a recent paper published by the agency.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.